Plant Name: Dendrobium amplum
Taxonomic Information:
Plant ID: NPO19966
Plant Latin Name: Dendrobium amplum
Taxonomy Genus: Dendrobium
Taxonomy Family: Orchidaceae
Plant External Links:
NCBI TaxonomyDB:
234050
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD1; | |
| BCHE; ACHE; | |
| HIF1A; | |
| SMN1;SMN2; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.398E-09 | 2.663E-05 | CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.446E-09 | 2.663E-05 | BCHE, CYP1A2, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0042737; drug catabolic process | 1.417E-07 | 6.172E-04 | ACHE, CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.417E-07 | 6.172E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.930E-07 | 7.004E-04 | ACHE, BCHE |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.828E-07 | 2.675E-03 | CYP1A2, CYP2C19, CYP2D6 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 2.873E-06 | 6.256E-03 | ACHE, BCHE, DRD1 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 8.667E-06 | 1.537E-02 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.271E-05 | 1.537E-02 | CYP1A2, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0004497; monooxygenase activity | 9.476E-06 | 1.537E-02 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.319E-05 | 2.405E-02 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0016705; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 4.109E-05 | 3.437E-02 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.517E-05 | 3.513E-02 | CYP1A2, CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.858E-05 | 3.648E-02 | CYP1A2, CYP2D6 |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 5.336E-04 | 1.844E-01 | CYP1A2, CYP2C19, CYP2D6, DRD1 |
| CC | GO:0044464; cell part | GO:0005641; nuclear envelope lumen | 3.722E-03 | 5.513E-01 | BCHE |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 4.210E-03 | 5.914E-01 | CYP1A2, CYP2C19, CYP2D6, DRD1, LMNA |
| CC | GO:0043226; organelle | GO:0016607; nuclear speck | 1.199E-02 | 8.806E-01 | HIF1A, LMNA |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 1.481E-02 | 9.572E-01 | DRD1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.253E-06 | 1.138E-04 | CYP2D6, CYP1A2, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.262E-05 | 1.271E-03 | CYP1A2, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.653E-04 | 5.134E-03 | CYP2D6, CYP1A2 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.091E-03 | 7.634E-03 | CYP2D6, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.867E-04 | 5.134E-03 | CYP1A2, CYP2C19 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.786E-02 | 6.911E-02 | CYP1A2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 2.668E-02 | 6.911E-02 | HIF1A |
| 09160 Human Diseases | 09165 Cardiovascular diseases | hsa05410 | Hypertrophic cardiomyopathy (HCM) | 3.674E-02 | 6.911E-02 | LMNA |
| 09160 Human Diseases | 09165 Cardiovascular diseases | hsa05414 | Dilated cardiomyopathy | 3.979E-02 | 6.911E-02 | LMNA |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.248E-03 | 1.311E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
